Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements

References

• Spagnolo P, Cordier JF, Cottin V. Connective tissue diseases, multimorbidity and the ageing lung. Eur Respir J. 2016 May;47(5):1535–1558.
   PubMed Web of Science ®Google Scholar
• Kim EA, Lee KS, Johkoh T, et al. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics. 2002 Oct;22(suppl_1):S151–65.
   PubMedGoogle Scholar
• Nakajima A, Inoue E, Tanaka E, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39(5):360–367.
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med. 2011 Feb 1;183(3):372–378.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011 Aug;38(8):1636–1643.
   PubMed Web of Science ®Google Scholar
• Ishizuka M, Watanabe R, Ishii T, et al. Long-term follow-up of 124 patients with polymyositis and dermatomyositis: statistical analysis of prognostic factors. Mod Rheumatol. 2016;26(1):115–120.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007 Jul;66(7):940–944.
   PubMed Web of Science ®Google Scholar
• Castelino FV, Dellaripa PF. Recent progress in systemic sclerosis-interstitial lung disease. Curr Opin Rheumatol. 2018 Nov;30(6):570–575.
   PubMed Web of Science ®Google Scholar
• Gunnarsson R, Hetlevik SO, Lilleby V, et al. Mixed connective tissue disease. Best Pract Res Clin Rheumatol. 2016 Feb;30(1):95–111.
   PubMed Web of Science ®Google Scholar
• Milholland AV, Wheeler SG, Heieck JJ. Medical assessment by a Delphi group opinion technic. N Engl J Med. 1973 Jun 14;288(24):1272–1275.
   PubMed Web of Science ®Google Scholar
• Page A, Potter K, Clifford R, et al. Prescribing for Australians living with dementia: study protocol using the Delphi technique. BMJ Open. 2015 Aug 11;5(8):e008048.
   PubMed Web of Science ®Google Scholar
• Taylor E. We agree, don’t we? The Delphi method for health environments research. Herd. 2020 Jan;13(1):11–23.
   PubMedGoogle Scholar
• Hoffmann-Vold A-M, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020;2(2):e71–e83.
   PubMedGoogle Scholar
• Kondoh Y, Makino S, Ogura T, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021 Nov;59(6):709–740.
   PubMed Web of Science ®Google Scholar
• Eba J, Nakamura K. Overview of the ethical guidelines for medical and biological research involving human subjects in Japan. Jpn J Clin Oncol. 2022 May 31;52(6):539–544.
   PubMed Web of Science ®Google Scholar
• Morisset J, Vittinghoff E, Elicker BM, et al. Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model. Chest. 2017 Nov;152(5):999–1007.
   PubMed Web of Science ®Google Scholar
• Hozumi H, Fujisawa T, Nakashima R, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med. 2016 Dec;121:91–99.
   PubMed Web of Science ®Google Scholar
• Jandali B, Salazar GA, Hudson M, et al. The effect of anti-Scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis. ACR Open Rheumatol. 2022 4;Apr(4):345–351.
   Google Scholar
• Cereser L, Passarotti E, De Pellegrin A, et al. Chest high-resolution computed tomography in patients with connective tissue disease: pulmonary conditions beyond “the usual suspects”. Curr Probl Diagn Radiol. 2022 Sep-Oct;51(5):759–767.
   PubMed Web of Science ®Google Scholar
• d’Alessandro M, Bergantini L, Cameli P, et al. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review. Biomark Med. 2020 Jun;14(8):665–674.
   PubMed Web of Science ®Google Scholar
• Kaieda S, Gono T, Masui K, et al. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease. PLoS One. 2020;15(6):e0234523.
   PubMed Web of Science ®Google Scholar
• Zhong D, Wu C, Bai J, et al. Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: a meta-analysis. Medicine (Baltimore). 2020 Apr;99(16):e19695.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Kondoh Y, Swigris JJ, et al. Performance of the St George’s Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease. Respirology. 2018 Mar 25;23(9):851–859.
   Web of Science ®Google Scholar
• Wijsenbeek M, Suzuki A, Maher TM. Interstitial lung diseases. Lancet. 2022 Sep 3;400(10354):769–786.
   PubMed Web of Science ®Google Scholar
• Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019 Jun 27;380(26):2518–2528.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019 Oct 31;381(18):1718–1727.
   PubMed Web of Science ®Google Scholar
• Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 May;9(5):476–486.
   PubMed Web of Science ®Google Scholar
• Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020 Oct;8(10):963–974.
   PubMed Web of Science ®Google Scholar